drugset / Trial / NCT05688020

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

NCT05688020 ↗

Phase 4 Unknown 200 enrolled Assaf-Harofeh Medical Center
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Endoscopic resection of gastrointestinal lesions may prevent cancer. However, resection is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.

Timeline

Start
2023-02-01
Primary completion
2025-02
Completion
2026-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Epinephrine Other / unclassified — Other
Subject Tranexamic Acid Small molecule 100 mg Other